IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.

Keiko Takano Chisato Saeki Tsunekazu Oikawa Akihisa Hidaka Yusuke Mizuno Jinya Ishida Kazuki Takakura Masanori Nakano Yuichi Torisu Katsushi Amano Tomohisa Ishikawa Mikio Zeniya Akihito Tsubota Masayuki Saruta

Published in: Journal of gastroenterology and hepatology (2019)

Our findings point to the beneficial effects of long-term UDCA plus bezafibrate combination therapy for UDCA-refractory PBC patients, and IgM response can be a useful predictive biomarker of long-term clinical outcomes.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported